Antiarrhythmic effects of vernakalant in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with short QT syndrome type 1

(1) Background: Short QT syndrome (SQTS) may result in sudden cardiac death. So far, no drugs, except quinidine, have been demonstrated to be effective in some patients with SQTS type 1 (SQTS1). This study was designed to examine the potential effectiveness of vernakalant for treating SQTS1 patients...

Ausführliche Beschreibung

Bibliographische Detailangaben

Hauptverfasser:	Xu, Qiang (VerfasserIn) , Huang, Xuemei (VerfasserIn) , Meng, Zenghui (VerfasserIn) , Li, Yingrui (VerfasserIn) , Zhong, Rujia (VerfasserIn) , Li, Xin (VerfasserIn) , Cyganek, Lukas (VerfasserIn) , El-Battrawy, Ibrahim (VerfasserIn) , Akın, Ibrahim (VerfasserIn) , Zhou, Xiao-Bo (VerfasserIn) , Lan, Huan (VerfasserIn)
Dokumenttyp:	Article (Journal)
Sprache:	Englisch
Veröffentlicht:	9 April 2022
In:	Journal of cardiovascular development and disease Year: 2022, Jahrgang: 9, Heft: 4, Pages: 1-14
ISSN:	2308-3425
DOI:	10.3390/jcdd9040112
Online-Zugang:	Verlag, kostenfrei, Volltext: https://doi.org/10.3390/jcdd9040112 Verlag, kostenfrei, Volltext: https://www.mdpi.com/2308-3425/9/4/112
Verfasserangaben:	Qiang Xu, Xuemei Huang, Zenghui Meng, Yingrui Li, Rujia Zhong, Xin Li, Lukas Cyganek, Ibrahim El-Battrawy, Ibrahim Akin, Xiaobo Zhou and Huan Lan